Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

48.34USD
6:47pm GMT
Change (% chg)

$0.80 (+1.68%)
Prev Close
$47.54
Open
$48.16
Day's High
$49.77
Day's Low
$48.16
Volume
46,497
Avg. Vol
111,426
52-wk High
$49.77
52-wk Low
$27.94

Latest Key Developments (Source: Significant Developments)

Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK.SEES FY 2017 REVENUE $555 MILLION TO $560 MILLION.SEES Q1 2018 REVENUE $145 MILLION TO $160 MILLION.SEES FY 2017 REVENUE UP 14 PERCENT.- FOR FULL YEAR 2017, ANTICIPATES CASH AND CASH EQUIVALENTS AT YEAR END OF ABOUT $180 MILLION.- SEES 2018 TOTAL REVENUES FROM $715 MILLION TO $755 MILLION.SEES 2018 ADJUSTED NET INCOME $110 MILLION TO $125 MILLION.- FULL YEAR 2017 ADJUSTED NET INCOME IS ANTICIPATED TO BE $92 TO $96 MILLION.- FOR FULL YEAR 2017, ANTICIPATES NET INCOME OF $80 TO $84 MILLION.SEES 2018 NET INCOME $95 MILLION TO $110 MILLION.FY2017 REVENUE VIEW $547.9 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $659.4 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Emergent Biosolutions Awarded Department Of National Defence Contract
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Emergent Biosolutions Inc ::EMERGENT BIOSOLUTIONS AWARDED DEPARTMENT OF NATIONAL DEFENCE CONTRACT TO SUPPLY ANTHRASIL TO THE CANADIAN GOVERNMENT.HAS BEEN AWARDED CONTRACT BY DEPARTMENT OF NATIONAL DEFENCE VALUED AT ABOUT $8 MILLION TO DELIVER ANTHRASIL TO CANADIAN GOVERNMENT.  Full Article

Emergent Biosolutions reports third quarter results
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Emergent Biosolutions Inc :Emergent Biosolutions reports third quarter and nine months 2017 financial results; raises calendar year 2017 guidance.Q3 earnings per share $0.68.Q3 revenue $149.4 million versus I/B/E/S view $124.6 million.Q3 earnings per share view $0.41 -- Thomson Reuters I/B/E/S.Emergent Biosolutions Inc sees FY 2017 ‍total revenues $540 million to $560​ million.Emergent Biosolutions Inc sees ‍FY 2017 net income $70 million to $80​ million.Emergent Biosolutions Inc sees FY 2017 ‍adjusted net income $85 million to $95​ million.  Full Article

Emergent awarded BARDA contract for advanced development of NuThrax
Friday, 30 Sep 2016 

Emergent Biosolutions Inc : Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion . Contract includes options for an additional clinical study and post-marketing commitments valued at $48 million . Company anticipates that FDA could authorize NuThrax for emergency use as early as 2018 .Contract includes options for delivery of additional 7.5 million to 50 million doses of NuThrax, valued about $255 million to up to $1.4 billion.  Full Article

Pharmathene says "protests" Dept of Health and Human Services anthrax vaccine solicitation
Friday, 5 Aug 2016 

Pharmathene Inc: "Formal protest" against Department of Health and Human Services, challenging solicitation for "next-generation anthrax vaccine provider" . As per complaint, government's "request for proposals" written in a way that assures source award to Emergent Biosolutions, which makes anthrax vaccine ."Protest requests GAO suspend award under solicitation while it reviews Pharmathene's complaint".  Full Article

Emergent BioSolutions Q2 GAAP loss per share $0.27
Thursday, 4 Aug 2016 

Emergent Biosolutions Inc : Emergent BioSolutions reports second quarter and six months 2016 financial results . Q2 revenue $101.5 million versus i/b/e/s view $111.2 million . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Q2 GAAP loss per share $0.27 .Will continue to temporarily postpone its financial guidance for 2016 until further clarity is reached U.S. Government contracts.  Full Article

Emergent BioSolutions says "when issued" trading of Aptevo stock to start today
Wednesday, 20 Jul 2016 

Emergent Biosolutions Inc : Aptevo common stock will commence trading today, July 20, 2016, on a "when issued" basis under symbol "APVOV" on NASDAQ global select market . Emergent BioSolutions announces commencement of when issued trading of Aptevo common stock .Expects that dividend distribution will be paid on August 1, 2016.  Full Article

Emergent Biosolutions to repurchase shares for up to $50 mln
Friday, 15 Jul 2016 

Emergent Biosolutions Inc : Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock . Repurchase program will be funded using company's working capital. . As of March 31, 2016, company had cash and cash equivalents of approximately $341 million. .Term of board authorization of repurchase program is until December 31, 2017..  Full Article

Emergent BioSolutions' board approves spin-off of Aptevo Therapeutics
Monday, 11 Jul 2016 

Emergent BioSolutions Inc. : Emergent Biosolutions' Board Of Directors Approves Spin Off of Aptevo Therapeutics and sets record and dividend distribution dates and distribution ratio . Expects to complete distribution of aptevo common stock to emergent stockholders on august 1, 2016. . Aptevo expects its common stock to begin trading on a "when issued" basis shortly before july 22, 2016 record date under ticker "apvo wi." . Aptevo has applied for listing on nasdaq global market. . On august 1, 2016, aptevo common stock is expected to begin "regular way" trading on nasdaq under symbol "apvo." .Emergent will continue to trade on new york stock exchange under ticker symbol "ebs.".  Full Article

Emergent BioSolutions says FDA completed pre-approval inspection of manufacturing facility for BioThrax
Tuesday, 21 Jun 2016 

Emergent BioSolutions Inc : Approval inspection of Emergent BioSolutions' large-scale manufacturing facility for BioThrax . Company received a no action indicated decision and no form 483 observations. .SBLA has a prescription drug user fee act (PDUFA) target action date of August 15, 2016.  Full Article

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK